Quince Therapeutics downgraded by Citizens JMP
$QNCX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Citizens JMP downgraded Quince Therapeutics from Mkt Outperform to Mkt Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/30/2026 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 8/5/2025 | $9.00 | Mkt Outperform | Citizens JMP |
| 3/24/2025 | $10.00 | Outperform | Oppenheimer |
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
4 - Quince Therapeutics, Inc. (0001662774) (Issuer)
Primary and key secondary endpoint did not achieve statistical significance eDSP was generally well tolerated with no clinically meaningful safety concerns identified Company to cease clinical development of eDSP; Intends to preserve cash and explore available options Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced topline results from its pivotal Phase 3 NEAT clinical trial evaluating its lead asset, dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP), in patients with Ataxia-Telangiectasia (A-T). In the NEAT study, th
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced the poster presentation of previously published safety data from the long-term treatment of children with Ataxia-Telangiectasia (A-T) at the British Paediatric Neurology Association 2026 Annual Meeting taking place in Glasgow, Scotland January 28-30, 2026. The objective of the data analysis was to describe the safety profile of long-term use of the company's lead asset, encapsulated dexamethasone sodium phosphate (eDSP), in children with A-T who received eDSP for a minimum of two years. Key highlights re
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today announced that the last patient has completed their last visit in the company's pivotal Phase 3 NEAT (Neurological Effects of eDSP in Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial of its lead asset, encapsulated dexamethasone sodium phosphate (eDSP), in patients with Ataxia-Telangiectasia (A-T). The company expects to report topline results from this study in the middle of the first quarter of 2026. Dirk Thye, M.D., Quince's Chief Executive Officer and Chief Medical Officer, said, "Completing our piv
Citizens JMP downgraded Quince Therapeutics from Mkt Outperform to Mkt Perform
Citizens JMP initiated coverage of Quince Therapeutics with a rating of Mkt Outperform and set a new price target of $9.00
Oppenheimer initiated coverage of Quince Therapeutics with a rating of Outperform and set a new price target of $10.00
8-K - Quince Therapeutics, Inc. (0001662774) (Filer)
144 - Quince Therapeutics, Inc. (0001662774) (Subject)
SCHEDULE 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)
Marks major milestone with completion of enrollment in pivotal Phase 3 NEAT clinical trial evaluating lead asset, eDSP, for the treatment of A-T; topline results expected in first quarter of 2026 Closed financing priced at a premium bringing existing cash position to approximately $35 million; expected to provide runway through Phase 3 topline results and into at least second quarter of 2026 Entered into strategic relationship with Option Care Health to support commercial launch of eDSP in the U.S. Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. Hassan Abolhassani, Assistant Professor of Clinical Immunology and Research Specialists in the Department of Medical Biochemistry and Biophysics at the Karolinska Institutet in Stockholm, Sweden, to the company's Scientific Advisory Board (SAB). Dr. Abolhassani becomes the ninth member to join Quince's SAB, which is comprised of leading experts in Ataxia-Telangiectasia (A-T), biochemistry, neurology, immunology, genetic, hematology, pharmacology, and clinical practice. Dr. Mauro Magnani,
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, announced the appointment of Dr. William Whitehouse, Honorary Clinical Associate Professor of the School of Medicine at the University of Nottingham, and recently retired Consultant Paediatric Neurologist at Nottingham Children's Hospital, Nottingham University Hospitals NHS Trust, to the company's Scientific Advisory Board (SAB). Dr. Whitehouse joins seven founding members of Quince's SAB comprised of leading experts in biochemistry, neurology, immunology, hematology, pharmacology, and clinical practice. Dr. Mauro Magn
Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that its Board of Directors (the "Board") unanimously approved the adoption of a limited duration stockholder rights plan (the "Rights Plan") and declared a dividend distribution of one preferred share purchase right on each outstanding share of Quince's common stock. The dividend distribution will be made on April 17, 2023, payable to stockholders of record on that date, and is not taxable to stockholders. The Rights Plan is effective immediately and has a one-year duration, expiring on April 5, 2024.
SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)
SC 13D - Quince Therapeutics, Inc. (0001662774) (Subject)
SC 13G/A - Quince Therapeutics, Inc. (0001662774) (Subject)